BIOT Stock Overview
Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications.
No risks detected for BIOT from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr184.90|
|52 Week High||kr295.60|
|52 Week Low||kr137.10|
|1 Month Change||-25.68%|
|3 Month Change||-29.86%|
|1 Year Change||25.87%|
|3 Year Change||59.67%|
|5 Year Change||298.49%|
|Change since IPO||81.27%|
Recent News & Updates
Is Biotage (STO:BIOT) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Biotage (STO:BIOT) Has A Rock Solid Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
|BIOT||SE Life Sciences||SE Market|
Return vs Industry: BIOT underperformed the Swedish Life Sciences industry which returned 31.6% over the past year.
Return vs Market: BIOT exceeded the Swedish Market which returned 17.8% over the past year.
|BIOT Average Weekly Movement||5.7%|
|Life Sciences Industry Average Movement||9.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in SE Market||11.7%|
|10% least volatile stocks in SE Market||3.9%|
Stable Share Price: BIOT is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BIOT's weekly volatility (6%) has been stable over the past year.
About the Company
Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
Biotage Fundamentals Summary
|BIOT fundamental statistics|
Is BIOT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIOT income statement (TTM)|
|Cost of Revenue||kr466.55m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 11, 2022
|Earnings per share (EPS)||3.08|
|Net Profit Margin||17.11%|
How did BIOT perform over the long term?See historical performance and comparison
0.8%Current Dividend Yield
Is Biotage undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BIOT (SEK184.9) is trading above our estimate of fair value (SEK183.46)
Significantly Below Fair Value: BIOT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIOT is poor value based on its PE Ratio (60x) compared to the Swedish Life Sciences industry average (46x).
PE vs Market: BIOT is poor value based on its PE Ratio (60x) compared to the Swedish market (22.6x).
Price to Earnings Growth Ratio
PEG Ratio: BIOT is poor value based on its PEG Ratio (4.2x)
Price to Book Ratio
PB vs Industry: BIOT is overvalued based on its PB Ratio (11.2x) compared to the SE Life Sciences industry average (3.6x).
How is Biotage forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOT's forecast earnings growth (14.4% per year) is above the savings rate (0.3%).
Earnings vs Market: BIOT's earnings (14.4% per year) are forecast to grow faster than the Swedish market (4.3% per year).
High Growth Earnings: BIOT's earnings are forecast to grow, but not significantly.
Revenue vs Market: BIOT's revenue (10.9% per year) is forecast to grow faster than the Swedish market (5.1% per year).
High Growth Revenue: BIOT's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIOT's Return on Equity is forecast to be low in 3 years time (19.4%).
How has Biotage performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIOT has high quality earnings.
Growing Profit Margin: BIOT's current net profit margins (17.1%) are higher than last year (13.8%).
Past Earnings Growth Analysis
Earnings Trend: BIOT's earnings have grown by 11.7% per year over the past 5 years.
Accelerating Growth: BIOT's earnings growth over the past year (36%) exceeds its 5-year average (11.7% per year).
Earnings vs Industry: BIOT earnings growth over the past year (36%) underperformed the Life Sciences industry 68.7%.
Return on Equity
High ROE: BIOT's Return on Equity (18.7%) is considered low.
How is Biotage's financial position?
Financial Position Analysis
Short Term Liabilities: BIOT's short term assets (SEK784.0M) exceed its short term liabilities (SEK289.0M).
Long Term Liabilities: BIOT's short term assets (SEK784.0M) exceed its long term liabilities (SEK124.0M).
Debt to Equity History and Analysis
Debt Level: BIOT has more cash than its total debt.
Reducing Debt: Insufficient data to determine if BIOT's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BIOT's debt is well covered by operating cash flow (715%).
Interest Coverage: BIOT's interest payments on its debt are well covered by EBIT (9.2x coverage).
What is Biotage current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BIOT's dividend (0.81%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (0.98%).
High Dividend: BIOT's dividend (0.81%) is low compared to the top 25% of dividend payers in the Swedish market (3.37%).
Stability and Growth of Payments
Stable Dividend: BIOT's dividend payments have been volatile in the past 10 years.
Growing Dividend: BIOT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (48.1%), BIOT's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BIOT's dividends in 3 years are forecast to be well covered by earnings (34.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tomas Blomquist (51 yo)
Mr. Tomas Blomquist has been CEO and President of Biotage AB since November 6, 2019. Mr. Blomquist serves as Independent Director at Nolato AB (publ) since May 4, 2021. Mr. Blomquist served as the Chief Op...
CEO Compensation Analysis
Compensation vs Market: Tomas's total compensation ($USD521.79K) is below average for companies of similar size in the Swedish market ($USD756.57K).
Compensation vs Earnings: Tomas's compensation has increased by more than 20% in the past year.
Experienced Management: BIOT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: BIOT's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biotage AB (publ)'s employee growth, exchange listings and data sources
- Name: Biotage AB (publ)
- Ticker: BIOT
- Exchange: OM
- Founded: 1969
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr12.200b
- Shares outstanding: 65.98m
- Website: https://www.biotage.com
Number of Employees
- Biotage AB (publ)
- Box 8
- Uppsala County
- 751 03
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 21:13|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.